ARTHEx Biotech Publishes First Demonstration of Improvement in a DM1-related Behavioral Alteration in a Preclinical Model of Myotonic Dystrophy Type 1 (DM1)

Contributed by: PR Newswire

Images

PR Newswire associated0

Tags

ARTHEx-Biotech-DM1

More Like This

PR Newswire associated0

ARTHEx Biotech Appoints Christian Freitag, M.D., as Chief Medical Officer

BioArctic receives Orphan Drug Designation for exidavnemab the US

PR Newswire associated0

AMO Pharma Announces Preclinical Data Showing AMO-02 Improves Muscle Function, Glucose Handling and CNS function in Mouse Models of Duchenne Muscular Dystrophy

Exidavnemab phase 2a study expanded to include MSA patients

AnnJi Pharmaceutical Company Announces Positive Phase 1/2a Results for AJ201 in Spinal and Bulbar Muscular Atrophy (SBMA) Patients

Arctic Therapeutics Announces €26.5M Oversubscribed Series A Financing

Business Wire logo

AviadoBio Presents Positive Preclinical Data for AVB-406 Program in Alzheimer’s Disease and Other Tauopathies at ASGCT 2026

Business Wire logo

Prothena’s Partner Bristol Myers Squibb Obtains Fast Track Designation from the U.S. FDA for BMS-986446 (PRX005), an Anti-MTBR-Tau-Targeting Antibody, for the Treatment of Alzheimer’s Disease